DISCOVER - Clinical Trial

What is the Purpose of this Study?


We are doing this study to find out if a new drug called dupilumab (the study drug) is a safe and effective option for people with atopic dermatitis who have darker skin tones. Specific information about the skin tones relevant to this study is included in the eligibility section below.

What is the Condition Being Studied?

Atopic Dermatitis (Eczema)

Who Can Participate in the Study?

Key Eligibility

Adults and children ages 12+ who:
- Are diagnosed with atopic dermatitis
- Have skin tone that is classified as 4, 5, or 6 on the Fitzpatrick scale

You can assess your skin tone according to the Fitzpatrick scale on the National Library of Medicine’s website:

For more information about this study, please contact the study team at

Age Group
Adults, Children

What is Involved?


If you or your child choose to join this study, your/their participation will last for up to 29 weeks (includes a screening period of up to 5 weeks to confirm that you/they are eligible). If you/they are eligible, you/they will take the study drug as an injection (shot) every 2 weeks. You/your child will get the study drug in our clinic the first time, and we will teach you how to give yourself or your child the shots at home for the remaining doses. Study participants will get up to 12 doses of the study drug.

Study participants will visit our clinic at least 9 times during the study, which includes the screening period. During these visits, you/your child will:
- Have a physical exam
- Have blood draws
- Answer questionnaires

Study Details

Full Title
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients with Moderate-to-Severe Atopic Dermatitis
Principal Investigator
Protocol Number
IRB: PRO00112395
NCT: NCT05590585
Phase IV
Enrollment Status
Open for Enrollment